Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients

被引:18
作者
Ahmed, Tamer A. [1 ]
Hayslip, John [2 ,3 ]
Leggas, Markos [1 ,2 ]
机构
[1] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA
[2] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA
[3] Univ Kentucky, Div Hematol, Lexington, KY 40536 USA
关键词
Simvastatin; Pharmacokinetics; High-dose; Leukemia; CELL-PROLIFERATION; LOVASTATIN; TRIAL; MIGRATION; STATINS; PLASMA; ACID;
D O I
10.1007/s00280-013-2326-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the pharmacokinetics of simvastatin at the maximum tolerated dose (MTD) of 7.5 mg/kg, twice daily, in the context of a pilot trial enrolling patients with recurrent and refractory chronic lymphocytic leukemia. Patients received simvastatin orally at MTD for 7 days during a 21-day cycle for 6 cycles. Blood samples were collected during cycle 1. Simvastatin lactone and carboxylate concentrations were measured in plasma and peripheral blood mononuclear cells (PBMCs) using a validated HPLC-MS/MS assay. Patients accrued to this study showed high variability in their exposure to simvastatin. Exposure was dose proportional (AUC and C (max)) as compared to those receiving standard hyperlipidemia therapy. Peak plasma concentrations ranged from 0.08 to 2.2 and from 0.03 to 0.6 mu M for simvastatin lactone and carboxylate, respectively. Our study shows that when simvastatin is administered at its MTD, only low micro-molar concentrations are achieved in plasma and PBMCs, which is consistent with the results observed in previous studies with lovastatin, but far lower than the concentrations required for anticancer effects in vitro. However, whether simvastatin at its MTD can confer therapeutic benefits to patients still remains to be determined.
引用
收藏
页码:1369 / 1374
页数:6
相关论文
共 20 条
[1]  
Ahmed Tamer A, 2012, J Pharm Anal, V2, P403, DOI 10.1016/j.jpha.2012.07.010
[2]  
Bouterfa HL, 2000, ANTICANCER RES, V20, P2761
[3]   Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status [J].
Cemeus, Catia ;
Zhao, Tong T. ;
Barrett, Gordon M. ;
Lorimer, Ian A. ;
Dimitroulakos, Jim .
JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (01) :9-17
[4]  
Crick DC, 1998, J NEUROCHEM, V70, P2397
[5]   REGULATION OF THE MEVALONATE PATHWAY [J].
GOLDSTEIN, JL ;
BROWN, MS .
NATURE, 1990, 343 (6257) :425-430
[6]   Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies [J].
Holstein, SA ;
Knapp, HR ;
Clamon, GH ;
Murry, DJ ;
Hohl, RJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) :155-164
[7]   A Population Pharmacokinetic-Pharmacodynamic Model for Simvastatin that Predicts Low-Density Lipoprotein-Cholesterol Reduction in Patients with Primary Hyperlipidaemia [J].
Kim, Jimyon ;
Ahn, Byung-Jin ;
Chae, Hong-Seok ;
Han, Seunghoon ;
Doh, Kichan ;
Choi, Jeongeun ;
Jun, Yong K. ;
Lee, Yong W. ;
Yim, Dong-Seok .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 (03) :156-163
[8]   A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix [J].
Knox, JJ ;
Siu, LL ;
Chen, E ;
Dimitroulakos, J ;
Kamel-Reid, S ;
Moore, MJ ;
Chin, S ;
Irish, J ;
LaFramboise, S ;
Oza, AM .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (04) :523-530
[9]   Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets [J].
Konstantinopoulos, Panagiotis A. ;
Karamouzis, Michalis V. ;
Papavassiliou, Athanasios G. .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (07) :540-555
[10]   A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme [J].
Larner, J ;
Jane, J ;
Laws, E ;
Packer, R ;
Myers, C ;
Shaffrey, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (06) :579-583